Reference

1. Holford N. Clinical pharmacokinetics and pharmacodynamics: the quantitative basis for therapeutics. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical pharmacology, 3rd ed. New York: McGraw-Hill, 1992:951–64.
2. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755–73.
3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742–51.
4. Kollef MH, Sherman G,Ward S, Fraser VJ. Inadequate antimicrobial treatment of    infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–74.
5. Kumar A, Roberts D,Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589–96.
6. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657–68.
7. Von Gelder T, van Schaik, Hesselink DA (2013). Practicability of pharmacogenetics in      transplantation medicine. Clin. Pharmacol. Ther. doi: 10.1038/clpt.169.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10; quiz 11–12.
9. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug. Nat Rev Microbiol 2004; 2: 289–300.
10. Kale Pramod.M , Shree Ambabai Talim Sanstha’s Diploma In Pharmacy , College, Miraj.     Wanlesswadi, Miraj-Sangli Rd, Miraj416414. Maharashtra, India
11. parthasarthi G Parthasarthi, Karin Nyfort-Hansen, A textbook of Clinical Pharmacy Practice-Essential Concepts and skills, 2nd Edition, Universities Press, 2012. Pg 395-397.
12. 12. Holford N. Clinical pharmacokinetics and pharmacodynamics: the quantitative basis for therapeutics. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical pharmacology, 3rd ed. New York: McGraw-Hill, 1992:951–64.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10; quiz 11–12.
14. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotech 2011; PMID 21554211.
15. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840–51.
16. Bilgrami I, Roberts JA,Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J.Meropenem dosing in critically ill patients with sepsis recieving high volume continuous veno-venous hemofiltration. Antimicrob AgentsChemother 2010; 54: 2974–8.
17. Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 2009; 64: 929–37.
18. Lipman J,Wallis SC, Boots RJ. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003; 97: 1149–54.
19. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1–16.
20. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39:215–31.
21. Philip D. Walson.Therapeutic drug monitoring in special populations. Clinical Chemistry 1998; 44:2; 415–419.
22. Dr Jason Roberts, Burns Trauma and Critical Care Research Centre, The University of Queensland, Level 3 Ned Hanlon Building, Royal Brisbane and Women’s Hospital, Butterfield Street, Brisbane, Queensland 4029, Australia.
23. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674–81.
24. Mergenhagen KA, Borton AR. Vancomycin Nephrotoxicity: A Review. Journal of Pharmacy Practice 2014; 27(6) :545-553.
25. Sawchuk RJ, Zaske DE, Cipolle RJ,Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362–9.
26. MacGowan A, Reeves D. Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Chemother 1994; 34: 829–37
27. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605–9.
28. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5.
29. Begg EJ, Barclay ML. Aminoglycosides – 50 years on. Br J Clin Pharmacol 1995; 39: 597–603.
30. Van Lent-Evers NA,Mathôt RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63–73.
31. Norris R,Martin J, Thompson E, Ray J, Fullinfaw R, Joyce D, Barras M, Jones G, Morris R. Current status of therapeutic drug monitoring in Australai and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit 2010; 32: 615–23.
32. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925–42.
33. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.Am J Health Syst Pharm 2009; 66: 82–98. 
34. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325 7.
35. Jeffres MN, Isakow W, Doherty JA,McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care–Associated Pneumonia. Chest 2006; 130: 947–55. 
36. Potoski BA, Paterson DL. Appropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia. Chest 2007; 132: 1101–3.
37. Roberts JA, Taccone FS, Udy AA, Jacobs F, Louis J-L, Lipman J. Vancomycin dosing in critically ill patients – robust methods for improved continuous infusion regimens. Antimicrob Agents Chemother 2011; 55: 2704–9.
38. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10; quiz 11–12.
39. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug. Nat Rev Microbiol 2004; 2: 289–300.
40. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32–8.
41. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725–30.
42. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357–63.
43. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above theminimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345–51.
44. Samanidou VF, Evaggelopoulou EN, Papadoyannis IN. Development of a validated HPLC method for the determination of four penicillin antibiotics in pharmaceuticals and human biological fluids. J Sep Sci 2006; 29: 1550 60.
45. McWhinney BC,Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr 2010; 878: 2039–43
46. Roberts JA, Hope WW, Lipman J. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 2010; 35: 419–20.
47. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53: 1863–7. J. A. Roberts et al. 34 / 73:1 / Br J Clin Pharmacol
48. Hidayat LK, Hsu DI, Quist R, Shriner KA,Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.Arch Intern Med 2006; 166: 2138–44.
49. Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010; 32: 97–101.
50. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605–10.
51. Rayner CR, Forrest A,Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411–23.
52. Zoller M, Maier B, Hornuss C, Neugebauer C, Döbbeler G, Nagel D, Holdt L-M, Bruegel M, Weig T, Grabein B, Frey L, Teupser D, Vogeser M, Zander J: Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 2014, 18: R148.
53. Richards and Brink: Therapeutic drug monitoring: linezolid too? Critical Care 2014 18:525.
54. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81.
55. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance – what’s dosing got to do with it? Crit Care Med 2008; 36: 2433–40
56. Ray J, Gardiner I,Marriott D.Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003; 33: 229–34.
57. Abdullah A, Charles AP, Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update, Drugs (2014) 74:839–854.